STELLAR BIOTECHNOLOGIES, INC. (NASDAQ:SBOT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
Appointment of Dr. Deborah F. Aghib to the Board of Directors
On January 23, 2018, upon the recommendation of the Nominating and Corporate Governance Committee (the Nominating Committee) of the Board of Directors (the Board) of Stellar Biotechnologies, Inc. (the Company), and in accordance with the Articles of the Company, the Board voted to increase the size of the Board by one seat and appointed Deborah F. Aghib, Ph.D. as a director of the Company to fill a vacancy on the Board resulting from such increase in the size of the Board. Dr. Aghib will serve for a term that commences immediately and expires at the Company’s 2018 Annual Meeting of Shareholders, or until her earlier resignation or removal.
There is no arrangement or understanding between Dr. Aghib and any other person to which Dr. Aghib was selected as a director, and there are no related party transactions involving Dr. Aghib that are reportable under Item 404(a) of Regulation S-K. There are no material plans, contracts or arrangements to which Dr. Aghib is a party or in which she participates, nor has there been any material amendment to any plan, contract or arrangement by virtue of Dr. Aghib’s appointment.
The following is certain biographical information regarding Dr. Aghib:
Deborah F. Aghib, Ph.D. is an advisor and consultant to biotechnology and healthcare-related companies and organizations. She currently serves as an advisor to the boards and management of CellPly S.r.L. (since August 2017), BrainDTech S.r.L (since January 2016), Sanipedia S.r.L (since October 2014) and Neuro-Zone S.r.L. (since January 2007). From February 2014 to September 2014, she was a private equity consultant for CRG LP, a healthcare-focused investment firm. From 2013 to 2014 she was a Business Development and Strategy executive under a consulting arrangement for Theravance Inc. From February 2012 to December 2012, she served as Stellar’s chief business development executive under a consulting arrangement. Since October 2015, Dr. Aghib has served on the Advisory Board of Open Common Consortium, a cloud computing and data commons infrastructure that supports cancer medical research from the University of Chicago. She holds a Ph.D. in Molecular and Cellular Biology from the University of Milan and a Ph.D. in Human Genetics from the University of Pavia. She received a Laurea degree in Biology from the University of Milan.
Among other experience, qualifications, attributes and skills, Dr. Aghib’s broad scientific knowledge and significant international experience in developing long-term strategies for business development, licensing and asset spinoffs for drug discovery, medical device and companion diagnostics companies led to the conclusion of our Nominating Committee and our full Board that she is qualified to serve as a director of the Company.
On January 25, 2018, the Company issued a press release announcing the appointment of Dr. Aghib to the Board. A copy of the press release is attached hereto as Exhibit 99.1.
|
Item 9.01 |
Financial Statements and Exhibits. |
Stellar Biotechnologies, Inc. ExhibitEX-99.1 2 tv484013_ex99-1.htm EXHIBIT 99.1 Stellar Biotechnologies Appoints Pharma Licensing Expert to Board of DirectorsLOS ANGELES,…To view the full exhibit click here
About STELLAR BIOTECHNOLOGIES, INC. (NASDAQ:SBOT)
Stellar Biotechnologies, Inc. is a biotechnology company. The Company is engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH). KLH is an immune-stimulating protein. KLH can be used as an active pharmaceutical ingredient (API) and combined with a disease-targeting agent to create immunotherapies for the treatment of a range of diseases. The Company’s core business is developing and commercializing Keyhole Limpet Hemocyanin for use in immunotherapy and immunodiagnostic applications. The Company’s Stellar KLH product offerings include Stellar KLH protein for conjugation and as carrier molecule in immunotherapy development; Stellar KLH protein and enzyme-linked immunosorbent assay (ELISA) test kits for immune function testing, and Custom KLH formulations, adjuvants, conjugations and fill finishes for preclinical research and drug development applications.